Home > Blogs > Regulatory Roundup > FDA Unveils Cannabis Research Draft Guidance, Sends CBD Enforcement Policy to OMB, and Makes Public CBD Sampling Report to Congress

FDA Unveils Cannabis Research Draft Guidance, Sends CBD Enforcement Policy to OMB, and Makes Public CBD Sampling Report to Congress

Posted: July 24, 2020

It has been a busy summer for the cannabis and cannabis-derived products spaces. This month alone, the U.S. Food and Drug Administration (FDA or the Agency): (1) sent to the White House Office of Management and Budget (OMB) for review a “Cannabidiol Enforcement Policy” draft guidance; (2) announced the availability of another draft guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research”; and (3) made public its report to Congress, “Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent That Products are Mislabeled or Adulterated.”

Click here to read more.